First patient dosed in AdvanCell’s phase 1/2 trial for prostate cancer treatment
AdvanCell has announced that the first patient has been dosed with 212Pb-ADVC001 in its phase 1/2 trial for the PSMA-positive metastatic Castration Resistant Prostate Cancer (mCRPC) treatment.
212Pb-ADVC001 is designed to bind to PSMA, a clinically validated cell surface target that is often highly expressed in prostate cancer, with the drug having already been optimised for safety and efficacy and demonstrating potential best-in-class attributes during preclinical studies.
The phase 1/2 trial is a multi-centre, open-label study which will assess the safety and efficacy of the drug candidate in patients with PSMA-positive mCRPC, aiming to find a recommended phase 2 dose. Secondary objectives include measuring dosimetry, rPFS by RECIST and PSMA PET-CT and PSA response.
Andrew Adamovich, AdvanCell’s chief executive officer, commented: “The first patient dosed with an AdvanCell therapeutic candidate represents a major milestone for the company, our scientists, clinical trial sites and our patients. We believe that 212Pb is the ideal radioisotope to realise the full therapeutic power of Targeted Alpha Therapy. This promise is strongly supported by preclinical results for 212Pb-ADVC001, which demonstrate the potential for best-in-class safety and efficacy.”
Tolremo doses first patient in phase 1 trial for drug to combat transcriptional cancer drug resistance
Tolremo Therapeutics has announced that it has dosed the first patient in its first-in-human clinical …
Sanofi and Regeneron have announced results from the second investigational phase 3 NOTUS trial for …